Recombinant adeno-associated viral vectors (rAAVs) have been widely used for gene delivery in animal models, and are currently evaluated for human gene therapy after successful clinical trials in the treatment of inherited, degenerative or acquired diseases, such as Leber congenital amaurosis, Parkinson disease or heart failure. However, limitations in vector tropism, such as limited tissue specificity and insufficient transduction efficiencies of particular tissues and cell types, still preclude therapeutic applications in certain tissues. Wild-type adeno-associated viruses (AAVs) are defective viruses that require the presence of a helper virus to complete their life cycle. On the one hand, this unique property makes AAV vectors one of the safest available viral vectors for gene delivery. On the other, it also represents a potential obstacle because rAAV vectors have to overcome several biological barriers in the absence of a helper virus to transduce successfully a cell. Consequently, a better understanding of the cellular roadblocks that limit rAAV gene delivery is crucial and, during the last 15 years, numerous studies resulted in an expanding body of knowledge of the intracellular trafficking pathways of rAAV vectors. This review describes our current understanding of the mechanisms involved in rAAV attachment to target cells, endocytosis, intracellular trafficking, capsid processing, nuclear import and genome release with an emphasis on the most recent discoveries in the field and the emerging strategies used to improve the efficiency of AAV-derived vectors.
INTRODUCTION
Gene therapy consists of the introduction of a therapeutic nucleic acid into a target cell in order to (i) replace the function of a defective gene, (ii) increase the expression of a downregulated gene or (iii) reduce detrimental levels of a protein, via RNA interference or antisense technology. Gene transfer is considered the last and only option to treat certain life-threatening or otherwise debilitating diseases for which no other therapeutic strategy is available such as, for instance, genetic disorders, drug-resistant cancers, heart failure or neurodegenerative diseases. Despite significant progress in the field of non-viral DNA transfer, 1 in vivo delivery of unprotected nucleic acids has proven difficult because naked DNA is prone to rapid degradation in the extracellular milieu and in the cell cytoplasm. For successful transfection of a cell, the DNA has to be readily transported across the plasma membrane, escape from endocytic vesicles and finally cross the nuclear membrane. The transfection reagents developed so far have achieved considerable efficiencies in cell lines but the efficiency in vivo remains limited. Animal viruses, on the other hand, have evolved over millions of years in order to optimize the delivery of their genetic material into host cells and, despite potential issues relating to their clinical safety and/or their immunogenicity, viruses are still considered the most effective and promising vectors for in vivo gene delivery. Among the variety of viruses used as vectors for gene transfer (retroviruses, herpesviruses, adenoviruses, poxviruses, and so on), the most impressive therapeutic successes so far have been obtained with retrovirus vectors in the treatment of children suffering from X-linked severe combined immunodeficiency disease 2-4 and with adeno-associated virus (AAV)-derived vectors in the treatment of Leber congenital amaurosis, an inherited eye disease leading to retinal degeneration. [5] [6] [7] .
AAVs are small non-enveloped DNA viruses first discovered as contaminants of adenovirus preparations. 8 They belong to the genus dependovirus of the sub-family parvovirinae and the family parvoviridae and require co-infection with a helper DNA virus (adenovirus, herpesvirus or papillomavirus) to complete their productive replication cycle. 9 AAVs are non-pathogenic in humans or animals, and show a low immunogenicity in comparison with other viruses. 10 AAVs have an icosahedral capsid (22-26 nm in diameter) containing a linear, single-stranded DNA genome of approximately 4.7 kb that is flanked by two T-shaped inverted terminal repeats. The left hand of the viral genome contains the rep gene, encoding the non-structural proteins rep78, 68, 52 and 40 that are required for DNA replication and packaging. The right hand of the AAV genome contains the cap gene, encoding the capsid proteins VP1, VP2 and VP3 and a newly identified chaperone, the so-called assembly-activating protein, which is necessary for capsid formation. 11 The isolation of an infectious clone of AAV2 (refs 12,13) and the demonstration that the AAV2 backbone could be used to express foreign proteins in cultured cells 14, 15 paved the way for using AAVs as gene delivery vectors. In contrast to other viruses, such as first-and second-generation adenoviruses, which require several viral genes in cis for viral vector production, the inverted terminal repeats are the only cis-elements of the AAV genome necessary for DNA replication and packaging, and the entire rep and cap genes can be replaced by any sequence of interest within a size limit of approximately 5 kb. 16 Furthermore, any trans-gene flanked by AAV2 inverted terminal repeats can be packaged into the capsid of any of the nine AAV serotypes (AAV1-9) currently evaluated for in vivo transduction. 17, 18 This is of particular importance because different AAV serotypes show very different tissue tropisms (summarized in Table 1 ). [19] [20] [21] AAV vector DNA rarely integrates in the host cell genome but can lead to sustained, long-term transgene expression in non-dividing cells. 22 This makes AAVs particularly suitable for gene therapy of largely post-mitotic tissues, such as the brain, the retina, the liver, skeletal muscles or the heart.
CELLULAR BARRIERS TO AAV TRANSDUCTION
Despite the great potential of recombinant adeno-associated viral vector (rAAV) for in vivo gene transfer and the availability of several serotypes and a large number of capsid variants, 23 AAV-derived vectors display insufficient transduction efficiency in certain tissues and their relatively low organ specificity can be problematic for specific therapeutic applications. For instance, serotypes 1, 6 and 9, which are often referred to as 'cardiotropic' because of their efficient transduction of cardiomyocytes, also transduce other organs, especially the liver, to a significant extent following intravenous injection. Conversely, overall transduction levels are comparatively low for all serotypes in organs such as the brain, the pancreas or the kidneys following systemic injection. 20, 24 Like all non-enveloped DNA viruses, AAVs must balance the need for a high capsid stability to prevent degradation in the extracellular environment as well as within the cell (for example, by lysosomal proteases or the proteasome) with the capacity to readily release their genome in the nucleus of the target cell. Thus, AAV-based vectors must overcome several limiting and complex steps between the cell membrane and the nucleus, where they ultimately deliver their genome for successful transduction. First, the virion must bind to the surface of the target cell via one or more receptors/co-receptors. The second step consists in the uptake of the virus-receptor complex by endocytosis following invagination of the cell membrane. The next steps include the maturation of viruscontaining vesicles into more acidic endocytic compartments, followed by retrograde transport to at least the trans-Golgi or the medialGolgi, cis-Golgi, endoplasmic reticulum (ER)-Golgi intermediate compartment or even the ER. Those stages, which can be collectively characterized as 'endosomal trafficking' , trigger irreversible modifications of the viral capsid both because of the lower pH and through the (enzymatic) action of resident proteins of these compartments. 84 Retrograde transport is followed by escape of the viral particle into the cytoplasm. This is most likely followed by the nuclear import of the intact viral particle through the nuclear pore complex (see below). After nuclear translocation, single-stranded DNA is released by capsid uncoating and converted into double-stranded DNA to allow transgene expression.
Although receptor expression pattern and viral attachment are obviously important in determining the tropism of AAV vectors, there is now strong evidence that post-attachment steps, such as endosomal escape or nuclear import, can drastically alter transduction efficiency. In fact, almost each AAV trafficking stage, from endocytosis to nuclear import, can constitute a rate-limiting step in a serotype-and cell type-dependent manner. Although many details of AAV trafficking remain to be determined, the use of both chemical and genetic inhibitors and enhancers (Table 2 ) combined with fluorescence microscopy have greatly contributed to our understanding of AAV trafficking. Importantly, this increasing knowledge has also resulted in the development of novel strategies that might help in overcoming some of the limitations that AAV trafficking poses to successful transduction.
AAV ATTACHMENT: RECEPTORS AND CO-RECEPTORS Despite our rapidly growing knowledge about novel AAV serotypes, the vast majority of studies on AAV biology have been performed using AAV2 as a model, for reasons that are both historical (first AAV infectious clone) 12 and practical (ability to transduce efficiently common laboratory cell lines such as HeLa or HEK-293T). 15 Hence, AAV2 was the first serotype whose attachment receptor was investigated and identified as heparan sulfate proteoglycan (HSPG) by competition and overexpression assays. 25, 26 This finding was followed by the identification of several putative proteinaceous co-receptors such as fibroblast growth factor receptor 1, 26 integrin aVb5, 27 integrin a5b1, 28 laminin receptor 29 or hepatocyte growth factor receptor (Table 1) , 30 suggesting that AAV2 infection requires a primary glycan receptor together with a co-receptor for optimal attachment and internalization. However, independent studies have challenged the role of integrin aVb5 in AAV2 transduction 31 and, more recently, a high-throughput small interfering RNA screen failed to confirm a role of fibroblast growth factor receptor 1 or hepatocyte growth factor receptor in AAV2 transduction of human aortic endothelial cells. 32 Interestingly, naturally occurring AAV2 variants recovered from human subjects do not use HSPG as an attachment receptor, 33 which could suggest that AAV2 ability to bind HSPG constitutes a tissue culture adaptation, positively selected via multiple passages of AAV-contaminated adenovirus preparations in HEK293 cells. AAV2 capsid mutants deficient in HSPG binding show a markedly Intracellular transport of AAV M Nonnenmacher and T Weber reduced transduction of mouse liver but retain the ability to transduce cardiac muscle, 34 indicating that AAV2 can use alternative receptors. Overall, the identification of receptors used by many AAV serotypes has reinforced the general view that AAVs use proteoglycan conjugates as a primary receptor (HSPG for AAV2, AAV3 and AAV6) or O-or N-linked sugars (O-linked 2,3-sialic acid for AAV4, N-linked sialic acid for AAV1, AAV5 and AAV6, N-linked galactose for AAV9) together with a proteinaceous receptor (fibroblast growth factor receptor 1, integrins and/or hepatocyte growth factor receptor for AAV2, hepatocyte growth factor receptor for AAV3, epidermal growth factor receptor for AAV6, platelet derived growth factor receptor (PDGFR) for AAV5, 37/67kD laminin receptor (LamR) for AAV2, AAV3, AAV8 and AAV9) for efficient binding and endocytosis (Table 1) . Dual receptor requirement is frequently observed for other viruses 35 and is reminiscent of ligand-mediated activation and subsequent endocytosis of receptors such as fibroblast growth factor receptor 1, which require HSPG binding. 36 One exception to this rule would be bovine AAV, which requires a sialylated glycolipid, GM1 ganglioside, for transduction. 37 Most interestingly, recent data indicate that binding of AAV2 to HSPG not only allows virus attachment, but also induces a conformational change of the capsid. 38 This could suggest that the binding of AAV to its proteoglycan primary receptor 'locks' the virion in a transition state that may increase its affinity for the secondary receptor and consequently trigger endocytosis.
AAV ENDOCYTOSIS
Following attachment to surface receptors, AAV internalization occurs via endocytosis, a process that starts with the invagination of the plasma membrane domains containing virus-receptor complexes and is followed by the scission and release of the newly formed vesicle into the cell. In the case of AAV2, this process is fast and efficient, because the totality of virions bound to the cell surface can be internalized in about 30-60 min. 39, 40 Therefore, virus internalization per se is likely not a rate-limiting step for AAV2 transduction, at least in tissue culture. Mammalian cells have developed multiple mechanisms of endocytosis aimed at targeting and sorting membrane-bound or extracellular cargos toward specific intracellular compartments. Those pathways include, but are not restricted to, clathrin-mediated endocytosis, caveolae-mediated endocytosis, macropinocytosis, phagocytosis or several ill-characterized clathrin-and dynamin-independent Abbreviations: AAV, adeno-associated virus; BC3, VP1/2 basic cluster 3 168 RK4NN mutant; BR3K, highly basic VP1/2 basic cluster 3 167 A4K mutant; CFTR, cystic fibrosis transmembrane conductance regulator; CLIC/GEEC, clathrin-independent carriers/GPI-enriched endocytic compartment; EE, early endosome; EIPA, 5-(N-ethyl-N-isopropyl)amiloride; ER, endoplasmic reticulum; HD/AN, VP1 double mutant ( 75 HD4AN) with no PLA2 activity; LE, late endosome; NLS, nuclear localization signal; PP5, serine/threonine protein phosphatase 5; siRNA, small interfering RNA; TC-PTP, T-cell protein tyrosine phosphatase. a Transduction data are expressed as ratio to control infections and may represent experiments performed in various cell lines/animals/time points.
pathways. 41, 42 Early studies showed a partial (50 to 70%) inhibition of AAV2 uptake and transduction in cells overexpressing a dominantnegative mutant of dynamin, a protein involved in the scission of clathrin-coated pits and caveolae, 39, 40 suggesting that clathrinmediated uptake was the default pathway of AAV2 endocytosis. Later studies showed that inhibition of the Rac1 GTPase strongly decreased cellular uptake of AAV2 (ref. 43) and that expression of a constitutively active mutant of Rac1 dramatically increased transduction. 44 These observations were surprising because Rac1 is a major effector of macropinocytosis, a dynamin-independent fluid-phase endocytic pathway distinct from clathrin-mediated endocytosis, 45 and there is evidence that constitutively active Rac1 inhibits clathrin-mediated endocytosis. 46, 47 In addition, internalized AAV2 virions showed little or no co-localization with a fluorescently labeled adenovirus type 5, 40 which is known to enter target cells via clathrinmediated endocytosis. 48 Recently, our group revisited the nature of the endocytic mechanism of AAV2 endocytosis and we could not confirm a clear involvement of clathrin, dynamin or Rac1 in AAV2 transduction but instead found that viral infectious entry is dependent on membrane cholesterol, actin, Cdc42, Arf1 and GRAF1, which together define the recently characterized clathrin-independent carriers/GPI-enriched endocytic compartment (CLIC/GEEC) endocytic pathway. 49 Similarly, a genome-wide small interfering RNA screen has identified several components of CLIC/GEEC endocytosis as being essential for efficient AAV2 transduction in human aortic endothelial cells 32 and recent experiments show that the internalization mechanism of HSPG, the primary receptor for AAV2, shares many features of CLIC/GEEC. 50 In our study, CLIC/GEEC endocytosis was required for efficient transduction, whereas inhibition of dynamin activity by dynasore or by dominant-negative dynamin mutants had no effect. There is currently no clear explanation to this discrepancy with previous studies. One possibility is that the use of adenoviral vectors for protein overexpression in some of the aforementioned studies 39, 43, 44 could modify general cell homeostasis. Pre-infection with first-generation adenoviral expression vectors (that retain E2, E4 and VA, and sometimes E1 or E3, regions) shows a substantial cytopathic effect (our unpublished observations) and increases AAV2 transduction by at least one order of magnitude, [51] [52] [53] and it has been reported that adenovirus infection enhances trafficking of AAV2 to the nucleus. 54 Furthermore, adenovirus type 5 E4 region enhances the expression of adhesion proteins on the cell surface, 55 and E4orf1 partially localizes to clathrin vesicles 56 and modulates Rac1 and phosphatidylinositol 3 kinase activity. 57 Therefore, it cannot be excluded that the use of adenoviral vectors modulates AAV2 trafficking.
In our studies, inhibition of either dynamin or CLIC/GEEC only partially inhibited virus internalization, but simultaneous inhibition of both pathways completely blocked viral entry, which indicates that AAV2 can enter cells via at least two distinct pathways. 49 These observations are not restricted to AAV2, because a similar dichotomy has been suggested for AAV5, 58, 59 although this serotype reportedly uses a different endocytic mechanism. 60 Importantly, in the case of AAV2, only CLIC/GEEC is required for efficient transduction, suggesting that viral particles internalized via dynamin-dependent endocytosis are mostly directed toward a 'dead-end' compartment and seldom contribute to transduction. Thus, efficient endocytosis is necessary but not sufficient for AAV transduction. This notion is supported by the fact that NIH3T3 cells can internalize AAV2 virions as efficiently as HeLa or 293T cells, but they are not permissive to transduction because of impaired post-entry trafficking. 61 Strikingly, in vivo, experiments performed with several AAV serotypes show no strict correlation between intracellular viral DNA accumulation and transgene expression in various organs. 20, 24, 62 Another remarkable example of the coexistence of infectious and non-infectious endocytic pathways within the same cell was provided by Di Pasquale and Chiorini, 63 who showed that intact AAV4, AAV5 or bovine AAV (but not AAV2 or AAV6) viral particles could cross monolayers of polarized cells when applied on the apical side, by a process known as Virions are sorted toward the trans-Golgi network (TGN) along a retrograde transport pathway presumably involving trafficking via early endosomes (EEs), followed by late endosomes (LEs), perinuclear recycling endosomes (PNREs) or both. Capsid conformation changes and exposure of the phospholipase A2 (PLA2) domain (spikes) allows cytoplasmic release from the Golgi apparatus or the ER, and nuclear import via the NPC. After nuclear import, intact capsids accumulate in the nucleolus (No) before mobilization into the nucleoplasm (NP) and genome release by partial uncoating. Some of the steps indicated are hypothetical and have not been conclusively proven yet.
Intracellular transport of AAV M Nonnenmacher and T Weber transcytosis. Interestingly, drugs known to inhibit transcytosis strongly increased cell transduction, suggesting that polarized cells can redirect attached virions toward two separate endocytic pathways, one of which leads to transcytosis, and the other to nuclear transport and transgene expression. It is yet unclear whether this dichotomy reflects the use of a different receptor, but recent experiments by DiPasquale and colleagues indicate that bovine AAV uses a distinct receptor for transcytosis versus transduction. 64 Taken together, all these studies indicate that AAVs can be internalized through a variety of mechanisms, namely clathrin-mediated endocytosis, caveolae-mediated endocytosis, via the CLIC/GEEC pathway, or possibly through additional pathways (Figure 1 ) the nature of which will then commit the virions to either an infectious pathway (by ultimately delivering the virion to the nucleus) or to a non-infectious pathway (by targeting the virion to lysosome/proteasome system for degradation or by transporting it across epithelial cells by transcytosis). Thus, although endocytosis per se is not necessarily rate limiting from a strictly quantitative point, it constitutes a crucial step in irreversibly determining the fate of incoming AAV virions.
POST-ENDOCYTIC TRAFFICKING
In contrast to virus internalization, several lines of evidence indicate that intracellular trafficking of AAV is a rate-limiting, slow and inefficient process. In cultured cells, only a small fraction of viral particles access the nucleus within 16-20 h, while the majority accumulate in a perinuclear compartment. 40 AAV2 transduction can be efficiently blocked by lysosomotropic drugs such as bafilomycin A1, chloroquine or ammonium chloride that buffer endosomal pH, indicating that endosome acidification is necessary for AAV2 processing, 40, 51, 65 and inhibition of transduction by brefeldin A suggests that transport steps involving the Golgi apparatus are involved. 51 The retrograde transport intermediates used by AAV are not yet completely defined but, at least for AAV2 and AAV5, incoming virions appear to be, at a minimum, transported to the Golgi apparatus before their release in the cytoplasm. 53, 59, 66 Previous studies indicate that a fraction of AAV2 virions transit via late and/or recycling endosomes enriched in Rab7 and Rab11, respectively. 67 AAV retrograde transport from an early endosomal compartment toward the trans-Golgi network is possibly similar to previously described pathways involved in trafficking of bacterial toxins 68, 69 or other non-enveloped DNA viruses such as SV40 or murine polyomavirus. [70] [71] [72] The transport of AAVs within the endomembrane system induces profound changes in capsid conformation that are required for efficient transduction. 73 Perhaps the most convincing evidence for the necessity of endosomal processing of AAV came from a study by Sonntag et al., 65 who showed that microinjection of intact virus in the cytoplasm-and even in the nucleus-of HeLa cells resulted in very low transduction. In the same study, the authors also observed that transduction could be blocked by cytoplasmic injection of antibodies targeted to the intact capsids or to the N-terminal part of VP1 and VP2. In conclusion, these experiments demonstrate that (i) the AAV2 capsid must undergo a conformational change in the endocytic system, (ii) passage of the virions through the cytoplasm is an obligatory stage in transduction, (iii) endosomal processing exposes the VP1 and VP2 N-terminal domains outside of the capsid and (iv) the presence of capsids with externalized VP1 and/ or VP2 N-termini in the cytoplasm is required for transduction. The N-terminal domains of VP1, which is buried inside the capsid in intact virions, 74 contains a phospholipase A2 domain that has been shown to be necessary for endosomal escape and transduction [75] [76] [77] [78] as well as three basic clusters (BC1, 2 and 3) that presumably act as nuclear localization signals for the viral capsid. 65, 79 Taken together, these observations suggest that within the endocytic system a conformational change exposes the VP1 and VP2 N-termini outside the capsid, which then allows the virus to escape the endomembrane compartment into the cytoplasm. Such process has been observed for several non-enveloped viruses, including papillomavirus, 80 polyomavirus 81 and adenovirus. 82 Presumably, once in the cytoplasm, the basic residue clusters of VP1 or VP2 would then mediate the nuclear import of full virions via the nuclear pore complex. AAV2 virions carrying a mutation in either the phospholipase A2 domain or the first BC in VP1 accumulate in the Golgi apparatus, which suggests that (i) exposure of the VP1 phospholipase A2 domain is not necessary for endosome-to-Golgi retrograde transport and (ii) that the endosomal release may occur from the Golgi apparatus, the ER-Golgi intermediate compartment, or the ER. 53, 83 In vitro exposure of AAV2 to acidic pH (pH 4-5) does not induce VP1/2 N-termini externalization. 65 This indicates that while endosome acidification is necessary for AAV2 processing, alone it is insufficient for VP1/2 externalization. Thus, endosomal acidification could be necessary for vesicular trafficking and/or dissociation of the virus-receptor complex, but insufficient for capsid conformational modifications and endosomal escape. Recent studies indicate that endosomal cathepsins B and L are necessary for transduction by 'priming' the capsids by partial proteolysis, 84 but it is yet uncertain whether this interaction modulates endosomal escape or a later step. Strikingly, cathepsin digestion of AAV2 and AAV8 showed a different cleavage pattern, which could be partially responsible for the fact that AAV2 and AAV8 show different uncoating kinetics. 85 Apparently, AAV5 was not sensitive to cathepsin B or L proteolysis indicating that this process is not conserved among all AAV serotypes. 84 
NUCLEAR IMPORT
The mechanism allowing AAV particles to cross the nuclear membrane is still poorly understood, but converging evidence suggest that intact particles are translocated into the nucleus before DNA release. Intact virions can still be detected inside the nucleus by immunofluorescence microscopy, 40, 43, 53, 86 nuclear microinjection of antibodies against intact capsids blocks transduction, 65 and fully infectious virions can be recovered from infected cell nuclei. 86 Based on poor infectivity of virions with exposed VP1/2 N-termini following cytoplasmic injection, Kleinschmidt and colleagues 65 suggested that AAV2 nuclear import was inefficient and rate limiting. However, this phenomenon could reflect an incomplete processing of the capsid rather than a low rate of nuclear import. Given the complexity of capsid modifications in the endomembrane system, as discussed earlier, it is challenging to evaluate the efficiency and kinetics of AAV nuclear import per se.
The BC2 and BC3, shared by the N-termini of VP1 and VP2, are necessary for transduction 65, 79 and together confer nuclear localization to a heterologous fusion protein, 65, 87 which strongly suggests that the BC2-3 domain would form a bipartite nuclear localization signal that allows virus nuclear import via the nuclear pore complex. AAV2 BC2 and BC3 are separated by a 23-amino-acids linker, which classifies them as a non-classical nuclear localization signal. Therefore, it is possible that AAV2 nuclear import relies on a direct interaction between the VP1/2 N-terminus and a member of the importin-b family, rather than with a classical importin-a/importin-b complex. [88] [89] [90] Once the virus has gained access to the nucleus, it is readily transported to the nucleolus, in which it is maintained as an intact particle until its egress into the nucleoplasm. 86 The process leading to AAV2 nucleolar localization is unknown, but it should be mentioned that AAV2 capsid has been reported to interact directly with nucleolin 91 and B23/nucleophosmin, 92 two major nucleolar proteins.
The exact role of nucleolar transport in AAV biology is uncertain, but the observation that nucleolin or nucleophosmin knock-down by RNA interference strongly increase AAV2 transduction 86 suggests that nucleolar transit may be dispensable or even detrimental for AAV2 uncoating and gene expression. The process of uncoating itself is not completely understood, but it is probable, as observed with autonomous parvoviruses, that viral DNA can be released without complete disassembly of the capsid. 93, 94 The kinetics of DNA release appear to be cell-and serotype dependent. In cells from cardiac origin, AAV6-packaged genomes have been reported to be released more efficiently than their AAV2-packaged counterparts, but the opposite trend is observed in HeLa cells. 95 Similarly, although AAV2, 6 and 8 show similar uptake and nuclear import rates during murine liver transduction, AAV6 and 8 appear to release their genome earlier than AAV2. Surprisingly, intact AAV2 virions are completely and rapidly dissociated following incubation with a liver nuclear extract. 85 Despite an apparent contradiction with the in vivo data, this observation could be explained by the phenomenon of nucleolar sequestration suggested by Johnson et al., 69 as discussed earlier; if AAV2 sequestration in the nucleolus prevents uncoating and genome release in vivo, one could expect the uncoating to be more efficient in an in vitro reaction, in which virions are directly exposed to nucleoplasmic factors. These observations also mirror those by Miao et al., 62 who described a striking discrepancy between substantial nuclear accumulation of AAV2 genomes and poor transduction in mouse liver. It will be very interesting to investigate further the possible relationship between nucleolar mobilization and the serotype-and tissue-specific differences in AAV transduction.
PROTEASOME INHIBITORS AND CAPSID UBIQUITINATION
Pioneer experiments by Douar et al. 51 showed that the proteasome inhibitor MG132 dramatically enhanced AAV2 transduction in cultured cells and delayed viral DNA decay. In addition, AAV2 and AAV5 capsids can be ubiquitinated both in vivo and in vitro, 96, 97 and transduction is increased, albeit to a lesser extent, following treatment with a E3 ubiquitin ligase inhibitor. 96 This led to the hypothesis that a significant fraction of incoming virions were targeted to proteasome degradation by ubiquitin conjugation of the capsid during cytoplasmic trafficking. However, this model was later challenged by several observations: (i) other proteasome inhibitors, such as LLnL, enhance transduction to the same extent as MG132 with no visible effect on viral DNA degradation, and (ii) the increased accumulation of viral DNA following MG132 treatment (about 2-to 3-fold 24-h postinfection) cannot account for the increase in transduction observed at the same time point (50-fold). Altogether, these observations clearly indicate that the dramatic increase in transduction caused by MG132 cannot be explained by an inhibition of proteasome-mediated virus degradation alone. Along those lines, it was proposed that proteasome inhibitors increase AAV trafficking to the nucleus by a yet unexplained mechanism, in a cell-and serotype-specific manner. [96] [97] [98] Interestingly, proteasome inhibitors are strong activators of the ER stress/misfolded protein response pathway, and recent studies have shown that ER stress induction could potentiate AAV2 transduction by an order of magnitude. 83 Consistently, heat-shock treatment 99 and alteration of cell redox status, 100 both known as potent ER stress inducers, increase AAV2 transduction to a comparable extent. Proteasome inhibitors also induce the formation of large nucleolar stress bodies enriched in proteasome, ubiquitinated cellular proteins, nucleoplasmic proteasome targets and heat-shock proteins, [101] [102] [103] reminiscent of the strong nucleolar accumulation of AAV2 observed after MG132 treatment. 53, 86 The exact role of capsid ubiquitination in AAV transduction is still poorly understood. For instance, it is not certain whether ubiquitination is beneficial or detrimental for AAV2 transduction. In the studies by Duan et al., transduction enhancement observed after E3 ligase inhibition might result from indirect pleiotropic effects of the drug on the cell metabolism. Mutagenesis of lysines residues exposed on the surface of the AAV2 capsid, the potential targets of ubiquitination, showed no improvement in infectivity. 34, 104, 105 Interestingly, in vitro capsid ubiquitination is much more efficient on denatured capsid proteins than on intact virions, 97 which led the authors to formulate the hypothesis that ubiquitination in vivo requires a conformational change of the capsid and the exposure of normally inaccessible lysine residues. Consistent with this view, bioinformatical analysis indicates that most of the potentially ubiquitinated lysine residues localize on the N-termini of VP1 and VP2 in AAV serotypes 1 to 12 (our unpublished observations). Hence, it will be interesting to study the function of these residues in AAV trafficking and transduction.
CAPSID PHOSPHORYLATION AND TYROSINE MUTANTS
A fascinating development in our understanding of the cellular roadblocks to AAV transduction came from a series of studies on the role of tyrosine phosphorylation in viral trafficking and gene expression. Initial reports from Qing et al. 106 showed that a cellular phosphoprotein, single-strand D-sequence binding protein, could bind to the inverted terminal repeat of the AAV2 genome and block complementary strand synthesis. General inhibition of tyrosine phosphorylation by genistein or tyrphostin-23, but also treatment with the DNA-damaging drug hydroxyurea or expression of adenovirus E4orf6 protein, dephosphorylated single-strand D-sequence binding protein and showed a strong concomitant increase in AAV2 transduction. [107] [108] [109] In parallel, T-cell protein tyrosine phosphatase or protein phosphatase 5 expression dramatically increased transduction. 110 Later studies from the same group demonstrated that phosphorylation inhibitors also had strong positive effects on virus transport to the nucleus. 98 Intriguingly, tyrphostin-23 did not show a synergistic or additive effect with MG132, which suggests that both drugs enhance transduction via a common mechanism. Simultaneously, Zhong et al. 111 found that intact AAV2 capsids could be phosphorylated in vitro by the epidermal growth factor receptor-protein tyrosine kinase, the specific target of tyrphostin-23. Most interestingly, in vitro phosphorylated AAV2 showed a threefold reduction in transduction, independently of second-strand DNA synthesis. A possible explanation was that exposed phosphotyrosines acted as a positive signal for capsid ubiquitination. Consistently, mutagenesis of highly conserved exposed tyrosine residues (Y444F, Y500F or Y730F) on AAV2 capsids enhanced transduction up to 10-fold in HeLa cells and 30-fold in mouse liver. Transduction by tyrosine mutants was not further enhanced by adenovirus co-infection, MG132 or tyrphostin-23 treatment, which again suggests that all these distinct treatments target a common step of AAV transduction, involving capsid phosphorylation and possibly ubiquitination. Since then, single or combined tyrosine mutants of AAV2 have been successfully tested in vitro in fibroblasts and mesenchymal stem cells 112 and in vivo in murine hepatocytes, 113, 114 and the retina. 115, 116 All studies so far showed a marked increase (10-to 100-fold) of transduction, successful transduction of non-permissive cells and an additive effect of multiple (up to three) tyrosine mutations. Improved transduction of mouse skeletal muscle was also obtained with tyrosine mutants of AAV6 vectors, and interestingly showed similarly enhanced long-term persistence of intracellular viral DNA. 117 
CONCLUDING REMARKS
The last decade has seen considerable progress in our understanding of AAV biology and the rapid identification of novel serotypes with different tissue tropism is opening new avenues for gene therapy applications. It is now well recognized that intracellular trafficking of AAV vectors constitutes a major limiting step in transduction. Not surprisingly, our knowledge of this highly complex, multistep process is still incomplete and future research is needed to improve our understanding of AAV capsid processing, endosomal escape, nuclear import and uncoating. This might be a challenging quest and it could prove difficult to isolate all of these steps from each other because early capsid modifications in the endosomal system could have major consequences on every downstream event, such as, for instance, the uncoating in the nucleus. The recent investigations about AAV capsid phosphorylation, which culminated in the discovery of tyrosine mutant vectors demonstrate that every discovery in the field of AAV trafficking can potentially translate into rapid and major improvements in gene therapy applications because it could allow to reduce dramatically the vector doses 111 or to transduce cell types refractory to wild-type capsid vectors. 112 Although it may seem counter-intuitive that targeted modification of evolutionary conserved surface residues improves viral transduction, one should keep in mind that AAV vectors are defective viruses. AAVs have evolved to co-infect target cells with a helper virus, and they are likely not optimized for autonomous infection. Almost every step of AAV transduction, from endosomal processing to transgene expression, might be enhanced by helper virus co-infection. This means that AAV vectors offer room for improvement and might be 'perfectible' by genetic manipulation of the capsid. This notion is supported by a growing body of evidence showing that directed evolution of AAV capsid from random mutants or shuffling libraries can create vectors displaying much higher transduction efficiency and/or specificity for selected cell types (as reviewed elsewhere in this issue). At first sight, AAV may seem an inefficient virus with recombinant AAV exhibiting a fairly high particle-to-infectivity ratio, 118 but recent studies indicate that in the presence of adenovirus, infectivity of wild-type AAV2 can approach a physical-to-infectious ratio of one, defining it as a near-perfect virus. 119 Recombinant AAV2 is nearly 100-fold less efficient than its wild-type counterpart in the same assay, tantalizingly opening the possibility that the sequence or secondary structure of the DNA packaged into AAV capsid may also influence transduction. If this hypothesis was confirmed, determination of sequence-specific DNAcapsid interactions could have great consequences for the design of AAV gene therapy vectors, as it could influence both the production and the infectivity of recombinant viruses, as previously observed for autonomous parvoviruses. 120, 121 
